Asoprisnil
Asoprisnil (pronounced as-oh-pris-nil) is a Selective progesterone receptor modulator (SPRM) that was under development by Schering AG and was in Phase III clinical trials for the treatment of symptoms associated with uterine fibroids and endometriosis. However, its development was discontinued in 2007 due to safety concerns.
Etymology
The term "Asoprisnil" is a coined name with no specific etymology. It is a common practice in pharmaceutical naming to create unique, non-descriptive names for new drugs.
Pharmacology
Asoprisnil belongs to the class of drugs known as Selective progesterone receptor modulators (SPRMs). These drugs act on the progesterone receptor, a type of nuclear receptor that is activated by the steroid hormone progesterone. SPRMs can have both agonistic (activating) and antagonistic (blocking) effects on the progesterone receptor, depending on the context.
Clinical Use
Asoprisnil was being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. Uterine fibroids are non-cancerous growths in the uterus that can cause heavy menstrual bleeding, pelvic pain, and other symptoms. Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside of the uterus, causing pain and potentially leading to fertility problems.
Development and Discontinuation
Asoprisnil was being developed by Schering AG, a German pharmaceutical company. It reached Phase III clinical trials, the stage at which a drug is tested in large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug to be used safely. However, in 2007, development of Asoprisnil was discontinued due to safety concerns.
Related Terms
- Selective progesterone receptor modulator
- Progesterone receptor
- Nuclear receptor
- Uterine fibroids
- Endometriosis
- Schering AG
External links
- Medical encyclopedia article on Asoprisnil
- Wikipedia's article - Asoprisnil
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski